Lara Bußmann

ORCID: 0000-0001-6302-0859
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Head and Neck Cancer Studies
  • Lung Cancer Treatments and Mutations
  • Cancer Diagnosis and Treatment
  • Lung Cancer Research Studies
  • Head and Neck Surgical Oncology
  • DNA Repair Mechanisms
  • HER2/EGFR in Cancer Research
  • Peptidase Inhibition and Analysis
  • Brain Metastases and Treatment
  • Ear and Head Tumors
  • PARP inhibition in cancer therapy
  • Hematopoietic Stem Cell Transplantation
  • Salivary Gland Tumors Diagnosis and Treatment
  • Cancer Immunotherapy and Biomarkers
  • Chronic Myeloid Leukemia Treatments
  • Chronic Lymphocytic Leukemia Research
  • Melanoma and MAPK Pathways
  • Glioma Diagnosis and Treatment
  • Cancer-related gene regulation
  • Crystallization and Solubility Studies
  • Olfactory and Sensory Function Studies
  • X-ray Diffraction in Crystallography
  • Monoclonal and Polyclonal Antibodies Research
  • Colorectal and Anal Carcinomas
  • Protein Degradation and Inhibitors

University Medical Center Hamburg-Eppendorf
2015-2024

Universität Hamburg
2015-2024

University Cancer Center Hamburg
2016-2023

Klinik und Poliklinik für Hals-, Nasen-, Ohrenheilkunde
2016-2021

Eppendorf (Germany)
2019

Universitätsklinik für Hals-, Nasen- und Ohrenheilkunde
2019

Universitäts-HNO-Klinik Heidelberg
2018

University Medical Center
2015

Abstract The oncogene epidermal growth factor receptor variant III (EGFRvIII) is frequently expressed in glioblastomas (GBM) but its impact on therapy response still under controversial debate. Here we wanted to test if EGFRvIII influences the sensitivity towards alkylating agent temozolomide (TMZ). Therefore, retrospectively analyzed survival of 336 GBM patients, demonstrating that standard treatment, which includes TMZ, expression associated with prolonged survival, only patients...

10.1038/s41388-020-1208-5 article EN cc-by Oncogene 2020-02-17

Abstract Overexpression of the epidermal growth factor receptor (EGFR) in head and neck squamous cell carcinomas (HNSCC) is considered to cause increased EGFR activity, which adds tumorigenicity therapy resistance. Since it still unclear, whether expression indeed associated with activity HNSCC, we analyzed relationship between auto-phosphorylation as a surrogate marker for activity. We used tissue micro array, fresh frozen HNSCC tumor corresponding normal samples large panel lines. While...

10.1038/s41598-019-49885-5 article EN cc-by Scientific Reports 2019-09-19

The goal of photopharmacology is to develop photoswitchable enzyme modulators as tunable (pro-)drugs that can be spatially and temporally controlled by light. In this context, the tyrosine kinase inhibitor axitinib, which contains a photosensitive stilbene-like moiety allows for E/Z isomerization, interest. Axitinib an approved drug targets vascular endothelial growth factor receptor 2 (VEGFR2) licensed second-line therapy renal cell carcinoma. photoinduced isomerization axitinib has been...

10.1002/cmdc.201800531 article EN ChemMedChem 2018-09-10

Abstract Signal transduction via protein kinases is of central importance in cancer biology and treatment. However, the clinical success kinase inhibitors often hampered by a lack robust predictive biomarkers, which also caused discrepancy between expression activity. Therefore, there need for functional tests to identify aberrantly activated individual patients. Here we present systematic analysis tyrosine head neck using such test—functional kinome profiling. We detected increased activity...

10.1002/ijc.33606 article EN International Journal of Cancer 2021-04-23

Abstract Background For loco-regionally advanced, but transorally resectable oropharyngeal cancer (OPSCC), the current standard of care includes surgical resection and risk-adapted adjuvant (chemo) radiotherapy, or definite chemoradiation with without salvage surgery. While transoral surgery for OPSCC has increased over last decade example in United States due to robotic surgery, this treatment approach a long history Germany. In contrast Anglo-Saxon countries, approaches have been used...

10.1186/s12885-020-07127-2 article EN cc-by BMC Cancer 2020-07-29

In head and neck squamous cell carcinoma (HNSCC), tumors negative for Human Papillomavirus (HPV) remain a difficult to treat entity the morbidity of current multimodal treatment is high. Radiotherapy in combination with molecular targeting could represent suitable, less toxic options especially cisplatin ineligible patients. Therefore, we tested dual PARP intra-S/G2 checkpoint through Wee1 inhibition its radiosensitizing capacity radioresistant HPV-negative HNSCC cells.Three lines (HSC4,...

10.1016/j.ctro.2023.100630 article EN cc-by-nc-nd Clinical and Translational Radiation Oncology 2023-04-20

Abstract Purpose Controversies exist in regard to surgical neck management total laryngectomies (TL). International guidelines do not sufficiently discriminate sides and sublevels, or minimal neck-dissection nodal yield (NY). Methods Thirty-seven consecutive primary TL cases from 2009 2019 were retrospectively analyzed terms of local tumor growth using a previously established imaging scheme, metastatic involvement, NY impact on survival. Results There was no case level IIB involvement any...

10.1007/s00432-020-03352-1 article EN cc-by Journal of Cancer Research and Clinical Oncology 2020-08-18

Abstract Background The multi‐kinase inhibitor sorafenib displays antitumoral effects in head and neck squamous cell carcinoma (HNSCC); however, the targeted kinases are unknown. Here we aimed to identify those determine mechanism of sorafenib‐mediated establish candidate biomarkers for patient stratification. Methods MET inhibitors crizotinib SU11274 were analyzed using a slide‐based antibody array, Western blotting, proliferation, survival assays. X‐rays used irradiations. Results...

10.1002/hed.25440 article EN Head & Neck 2018-12-15

Acute lymphoblastic leukemia (ALL) is the most common cause of cancer-related death in children. Despite significantly increased chances cure, especially for high-risk ALL patients, it still represents a poor prognosis substantial fraction patients. Misregulated proteins central switching points cellular signaling pathways represent potentially important therapeutic targets. Recently, inositol phosphatase SHIP1 (SH2-containing 5-phosphatase) has been considered as tumor suppressor leukemia....

10.3390/cells12131798 article EN cc-by Cells 2023-07-06

Abstract Background The oncogene epidermal growth factor receptor variant III (EGFRvIII) is expressed in approximately one-third of all glioblastomas (GBMs). So far it not clear if EGFRvIII expression induces replication stress GBM cells, which might serve as a therapeutical target. Methods Isogenetic EGFRvIII− and EGFRvIII+ cell lines with endogenous were used. Markers oncogenic such γH2AX, RPA, 53BP1, ATR, CHK1 analyzed using western blot, immunofluorescence, flow cytometry. DNA fiber...

10.1093/noajnl/vdab180 article EN cc-by-nc Neuro-Oncology Advances 2021-12-04

Background We have recently shown a frequent upregulation of Src-family kinases (SFK) in head and neck squamous cell carcinoma (HNSCC). Here we tested, if SFK targeting is effective especially HNSCC cells with upregulated signaling.

10.1055/s-0044-1784750 article EN Laryngo-Rhino-Otologie 2024-04-19

The use of primary tumor tissue in experimental and pre-clinical cancer research is becoming increasingly important. Especially the slice cultures specimen, so called ex vivo or explants, promises functional analysis under approximate physiological conditions. This includes screening testing targeted therapeutics directed against deregulated protein kinases. However, it unclear if indeed represent situ situation especially with respect to very sensitive transient molecular processes such as...

10.1016/j.oraloncology.2021.105603 article EN cc-by-nc-nd Oral Oncology 2021-11-16
Coming Soon ...